Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade
- PMID: 24927736
- PMCID: PMC4204763
- DOI: 10.1093/hmg/ddu300
Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade
Abstract
Mitotic index is an important component of histologic grade and has an etiologic role in breast tumorigenesis. Several small candidate gene studies have reported associations between variation in mitotic genes and breast cancer risk. We measured associations between 2156 single nucleotide polymorphisms (SNPs) from 194 mitotic genes and breast cancer risk, overall and by histologic grade, in the Breast Cancer Association Consortium (BCAC) iCOGS study (n = 39 067 cases; n = 42 106 controls). SNPs in TACC2 [rs17550038: odds ratio (OR) = 1.24, 95% confidence interval (CI) 1.16-1.33, P = 4.2 × 10(-10)) and EIF3H (rs799890: OR = 1.07, 95% CI 1.04-1.11, P = 8.7 × 10(-6)) were significantly associated with risk of low-grade breast cancer. The TACC2 signal was retained (rs17550038: OR = 1.15, 95% CI 1.07-1.23, P = 7.9 × 10(-5)) after adjustment for breast cancer risk SNPs in the nearby FGFR2 gene, suggesting that TACC2 is a novel, independent genome-wide significant genetic risk locus for low-grade breast cancer. While no SNPs were individually associated with high-grade disease, a pathway-level gene set analysis showed that variation across the 194 mitotic genes was associated with high-grade breast cancer risk (P = 2.1 × 10(-3)). These observations will provide insight into the contribution of mitotic defects to histological grade and the etiology of breast cancer.
Published by Oxford University Press 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Figures
References
-
- Hawkins G.A., Mychaleckyj J.C., Zheng S.L., Faith D.A., Kelly B., Isaacs S.D., Wiley K.E., Chang B.L., Ewing C.M., Bujnovszky P., et al. Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk. Cancer Genet. Cytogenet. 2002;137:1–7. - PubMed
-
- Guo Y., Zhang X., Yang M., Miao X., Shi Y., Yao J., Tan W., Sun T., Zhao D., Yu D., et al. Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer. J. Med. Genet. 2010;47:616–622. - PubMed
-
- Milam M.R., Gu J., Yang H., Celestino J., Wu W., Horwitz I.B., Lacour R.A., Westin S.N., Gershenson D.M., Wu X., et al. STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study. Gynecol. Oncol. 2007;107:71–74. - PubMed
-
- Ewart-Toland A., Dai Q., Gao Y.T., Nagase H., Dunlop M.G., Farrington S.M., Barnetson R.A., Anton-Culver H., Peel D., Ziogas A., et al. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis. 2005;26:1368–1373. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA128978/CA/NCI NIH HHS/United States
- U01 CA69417/CA/NCI NIH HHS/United States
- UM1 CA164920/CA/NCI NIH HHS/United States
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- R01 CA128978/CA/NCI NIH HHS/United States
- U19 CA148537/CA/NCI NIH HHS/United States
- U19 CA148065/CA/NCI NIH HHS/United States
- C1281/A12014/CRUK_/Cancer Research UK/United Kingdom
- CA098758/CA/NCI NIH HHS/United States
- U01 CA069417/CA/NCI NIH HHS/United States
- CA54281/CA/NCI NIH HHS/United States
- U01 CA069638/CA/NCI NIH HHS/United States
- CA116201/CA/NCI NIH HHS/United States
- U01 CA069467/CA/NCI NIH HHS/United States
- RFA-CA-06-503/CA/NCI NIH HHS/United States
- P30 CA68485/CA/NCI NIH HHS/United States
- 16565/CRUK_/Cancer Research UK/United Kingdom
- 1U19 CA148065/CA/NCI NIH HHS/United States
- C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
- 1U19 CA148537/CA/NCI NIH HHS/United States
- R01 CA100374/CA/NCI NIH HHS/United States
- CA63464/CA/NCI NIH HHS/United States
- C490/A10124/CRUK_/Cancer Research UK/United Kingdom
- C5047/A8384/CRUK_/Cancer Research UK/United Kingdom
- R01CA100374/CA/NCI NIH HHS/United States
- C1287/A 10710/CRUK_/Cancer Research UK/United Kingdom
- P50 CA116201/CA/NCI NIH HHS/United States
- UL1 TR000135/TR/NCATS NIH HHS/United States
- C1287/A12014/CRUK_/Cancer Research UK/United Kingdom
- R01 CA063464/CA/NCI NIH HHS/United States
- 090532/WT_/Wellcome Trust/United Kingdom
- P30 CA015083/CA/NCI NIH HHS/United States
- C5047/A15007/CRUK_/Cancer Research UK/United Kingdom
- 16563/CRUK_/Cancer Research UK/United Kingdom
- CRN-87521/CAPMC/ CIHR/Canada
- U01 CA69638/CA/NCI NIH HHS/United States
- U01 CA063464/CA/NCI NIH HHS/United States
- R01 CA077398/CA/NCI NIH HHS/United States
- R01 CA054281/CA/NCI NIH HHS/United States
- R01 CA132839/CA/NCI NIH HHS/United States
- P30 CA068485/CA/NCI NIH HHS/United States
- R01 CA77398/CA/NCI NIH HHS/United States
- 1U19 CA148112/CA/NCI NIH HHS/United States
- U19 CA148112/CA/NCI NIH HHS/United States
- U01 CA098758/CA/NCI NIH HHS/United States
- CA132839/CA/NCI NIH HHS/United States
- C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
- U01 CA69467/CA/NCI NIH HHS/United States
- R37 CA054281/CA/NCI NIH HHS/United States
- 16561/CRUK_/Cancer Research UK/United Kingdom
- 10124/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
